Alkermes ALKS
NASDAQ ALKS
$48.44 -1.74 (-3.47%)
At close: Aug 20, 2026 · 2:35 PM UTC

Alkermes (ALKS) Cash from Investing Activities (2010 - 2026)

Alkermes (ALKS) posted quarterly Cash from Investing Activities of -$2.4 million for Q2 2026, up 91.75% year-over-year from -$1.3 million in Q2 2025, and up 99.88% quarter-over-quarter from -$2.1 billion in Q1 2026.

Alkermes (ALKS) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Cash from Investing Activities for 17 consecutive years, with -$2.4 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Cash from Investing Activities rose 91.75% year-over-year to -$2.4 million; the TTM figure through Jun 2026 stood at -$1.8 billion (down 1130.68% YoY), while the FY2025 annual figure was $295.5 million, up 365.48% from the prior year.
  • Cash from Investing Activities advanced to -$2.4 million in Q2 2026 per ALKS's latest filing, from -$2.1 billion in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $322.3 million in Q4 2025 and bottomed at -$2.1 billion in Q1 2026.
  • Historically, Cash from Investing Activities has averaged -$105.9 million across 5 years, with a median of -$10.3 million in 2024.
  • Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 3838.54% — and 2026, when it tumbled 22919.16%.
  • Alkermes' Cash from Investing Activities stood at $27.7 million in 2022, then slumped by 175.64% to -$21.0 million in 2023, then soared by 33.87% to -$13.9 million in 2024, then soared by 2423.21% to $322.3 million in 2025, then slumped by 100.75% to -$2.4 million in 2026.
  • Business Quant data shows ALKS's Cash from Investing Activities at -$2.4 million in Q2 2026, -$2.1 billion in Q1 2026, and $322.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 43.89 Bn 42.93 Bn - -
2 Teva Pharmaceutical Industries 43.08 Bn 39.43 Bn 2.15 Bn -491.00 Mn
3 Zoetis 31.55 Bn 29.88 Bn 1.05 Bn -300.00 Mn
4 Takeda Pharmaceutical 28.60 Bn 22.80 Bn 5.10 Bn -550.24 Mn
5 United Therapeutics 22.14 Bn 19.48 Bn 683.80 Mn 87.50 Mn
6 Viatris 18.75 Bn 17.87 Bn 1.46 Bn -51.60 Mn
7 Neurocrine Biosciences 15.53 Bn 15.14 Bn 935.80 Mn -135.40 Mn
8 Elanco Animal Health 11.72 Bn 11.19 Bn 798.00 Mn -110.00 Mn
9 Dr Reddys Laboratories 10.13 Bn 9.96 Bn - -
10 Alkermes 8.10 Bn 7.45 Bn 397.90 Mn -2.41 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.41 Mn
Jun 30, 2026 -2.41 Mn
Mar 31, 2026 -2.08 Bn
Mar 31, 2026 -2.08 Bn
Dec 31, 2025 322.35 Mn
Dec 31, 2025 322.35 Mn
Sep 30, 2025 -6.74 Mn
Sep 30, 2025 -6.74 Mn
Jun 30, 2025 -29.21 Mn
Jun 30, 2025 -29.21 Mn
Mar 31, 2025 9.10 Mn
Mar 31, 2025 9.10 Mn
Dec 31, 2024 -13.88 Mn
Dec 31, 2024 -13.88 Mn
Sep 30, 2024 -109.33 Mn
Sep 30, 2024 -109.33 Mn
Jun 30, 2024 51.85 Mn
Jun 30, 2024 51.85 Mn
Mar 31, 2024 -39.95 Mn
Mar 31, 2024 -39.95 Mn